express
on 30 Mar 2003
Last Applicant/ Owned by
Benedenstraat 59
Leuven Vlaams-Brabant
BE
3000
Serial Number
78059170 filed on 19th Apr 2001
Registration Number
N/A
Correspondent Address
Chapel Hill NC 27517
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
biological , chemical, and enzyme preparations for medical and veterinary purposes, namely pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency; chemical reagents for medical and veterinary use, namely, clinical medical reagents; medical diagnostic reagents; medicines for human and veterinary purposes, namely, pharmaceutical preparations used in the Read More
Genetically engineered animal cells for in vitro production for medical or veterinary use of biological active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, including genetically engineered animals for in vivo production for medical or veterinary use of biologically active recombinant proteins or genetically engineered derivatives thereof using co-expression of a gene encoding a proprotein or precursor protein and a gene encoding a proprotein convertase, test-tube manufacture for medical or veterinary use of biologically active recombinant proteins genetically engineered derivatives thereof from a proprotein or precursor protein using a proprotein convertase, biologically active recombinant proteins or genetically engineered derivatives of plasma proteins such as blood clotting factors and albumin, biological active recombinant proteins or genetically engineered derivatives of brain proteins such as neuropeptides, polypeptide hormones and receptors, biologically active recombinant proteins or genetically engineered derivatives of growth and differentiation factors such as for instance members of the TGF- BETA/BMP superfamily, biologically active recombinant proteins or genetically engineered derivatives of growth factor receptors such as the type I insulin-like growth factor receptor, biologically active recombinant proteins or genetically engineered derivatives of viral proteins from viruses, such as for example HIV, Ebola virus, Marburg virus, influenza virus, biologically active recombinant protein or genetically engineered derivatives of toxins e.g. anthrax toxin, biologically active recombinant proteins or genetically engineered derivatives of a variety of enzymes such as metalloproteinases and proprotein convertases, biologically active recombinant proteins or genetically engineered derivatives of several cell-surface receptors, adhesion molecules, signaling proteins and extracelluar-martix proteins, biologically active recombinant proteins or genetically engineered derivatives of proteins or fragments thereof for production of vaccines, biological active recombinant proteins or genetically engineered derivatives of any natural occurring of artificially designed proprotein or precursor protein which requires the action of a proprotein convertase for cleavage into biologically active components
biological , chemical, and enzyme preparations for medical and veterinary purposes, namely pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency; chemical reagents for medical and veterinary use, namely, clinical medical reagents; medical diagnostic reagents; medicines for human and veterinary purposes, namely, pharmaceutical preparations used in the treatment of mammals with enzyme insufficiency or deficiency
Biological research, namely biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research, and viral research; blood bank services; research and development of new pharmaceutical and research products for others; Professional consultancy, namely, technical consultation in the field of biomedical research, biochemical research, genetic research, animal cell biotechnology research, agricultural research and viral research
No 78059170
No Service Mark
No
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
30th Mar 2003 | ABANDONMENT - EXPRESS MAILED |
19th Mar 2003 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
01st Oct 2002 | FINAL REFUSAL MAILED |
21st Aug 2002 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
26th Jun 2002 | NOTICE OF PUBLICATION |
18th Apr 2002 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
05th Feb 2002 | APPROVED FOR PUB - PRINCIPAL REGISTER |
06th Dec 2001 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
20th Jul 2001 | NON-FINAL ACTION MAILED |
17th Jul 2001 | ASSIGNED TO EXAMINER |